«memories of future»: change in verapamil significance in the treatment of patients with ischemic heart disease and arterial hypertension

Clicks: 186
ID: 208558
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #66 of 98 articles by views in environmental technology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract

The significance of verapamil in the treatment of patients with ischemic heart disease (IHD) and hypertension (HT) is considered. Data on the limited role of beta-blockers in the improvement of patient’s status in stable IHD, data about negative effect of heart rate (HR) reduction on the central aortic pressure, as well as the relationship between HR and risk of complications in the INVEST trial are presented. Verapamil therapy in patients with HT and IHD without heart failure/systolic dysfunction and/or recent myocardial infarction may have advantages due to achievement of the sufficient antiischemic effect with less HR reduction.

Reference Key
gilyarevskiy2015racionalna«memories Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;S. R. Gilyarevskiy
Journal environmental technology
Year 2015
DOI
10.1234/1819-6446-2014-6-672-678
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.